Category Archives: 2017 Patent Review

Hikma and West-Ward v. Vanda – Are Methods of Medical Treatment Patent-Eligible?

Posted on March 5, 2019 by Warren Woessner

Hikma Pharms. and West-Ward Pharms petition for cert. to reverse the Fed. Cir.’s decision in Vanda v. West-Ward that methods of medical treatment are patentable. The Supreme Court’s now-infamous Mayo decision, invalidated claims to a method for determining the optimal … Continue reading →

Posted in 2017 Patent Review | Tagged Hatch-Waxman, Hikma Pharmaceuticals, Mayo, Supreme Court, USPTO, West Ward-Pharmaceuticals | Leave a comment

Sea Change in IPR or Just an SOS? – Aqua Products, Inc. v. Matal

Posted on October 5, 2017 by Warren Woessner

Sitting en banc, a fractured Federal Circuit (Appeal no. 2015-1177 (Fed. Cir., Oct. 4, 2017)) released 140+ pages comprising five separate opinions (7 Judges “concur in result”). The majority held that, at least under the current PTO regulations: “The only … Continue reading →

Posted in 2016 Patent Review, 2017 Patent Review | Leave a comment

FDA Publishes “Purple Book” for Biologicals/Biosimilars

Posted on September 11, 2014 by Warren Woessner

In a major move to get organized for the oncoming wave of biosimilar applications, the FDA has published a “Purple Book” listing licensed (e.g., approved) biologicals and licensed interchangeable biosimilars. Rather than summarize the contents table of the book, linked … Continue reading →